Acceptability of a 250 mg levofloxacin formulation in children receiving TB preventive treatment
LFX 250 mg tablets have reasonable acceptability and could be used as an alternative to dispersible formulations, especially in children able to swallow tablets.
Authors
- Hendrik Simon Schaaf (ORCID: https://orcid.org/0000-0001-5755-4133)
- Susan E. Purchase (ORCID: https://orcid.org/0000-0002-9629-5952)
- Anneke Catharina Hesseling (ORCID: https://orcid.org/0000-0001-9399-9834)
- Suzanne Staples (ORCID: https://orcid.org/0000-0002-9049-8070)
- Neil Alexander Martinson (ORCID: https://orcid.org/0000-0002-0184-5705)
- James A. Seddon (ORCID: https://orcid.org/0000-0002-2296-2302)
- Lee Fairlie (ORCID: https://orcid.org/0000-0001-5327-1734)
- Trinh Duong (ORCID: https://orcid.org/0009-0003-1052-0827)
- Joanna Brigden
- Asanda Poswa
Institutions
- Desmond Tutu HIV Foundation (ZA)
- Johns Hopkins University (US)
- University of the Witwatersrand (ZA)
- Stellenbosch University (ZA)
- MRC Clinical Trials Unit at UCL (GB)
- Project Empower (ZA)
- Perinatal HIV Research Unit (ZA)
- University College London (GB)
- Imperial College London (GB)
Publication Details
- Journal
- IJTLD OPEN
- Published
- 2025-03-01
- DOI
- https://doi.org/10.5588/ijtldopen.24.0569
- Citations
- 5
- Primary Topic
- Pharmaceutical studies and practices
- Type
- article
- Field-Weighted Citation Impact
- 17.47